Better Health for All

APONTIS PHARMA AG's core business is Single Pill therapies for cardiovascular diseases. The START Study, published in a peer-reviewed journal, demonstrated significant health benefits, including a relative reduction in mortality of up to 49%, strokes by 46%, heart attacks by 38%, heart failure by 60%, and hospitalizations by 55%.

In 2021, Single Pill sales constituted 62% of total sales. The company has no reported revenue from products with negative health outcomes. For healthcare data responsibility, the START Study utilized anonymized medical claims data, and the article explicitly states that no ethical review or informed consent was needed, indicating a lack of explicit consent protocols for data usage.

Fair Money & Economic Opportunity

APONTIS PHARMA AG is a pharmaceutical company specializing in single pills for chronic diseases.

Its core business does not involve lending, insuring, moving, or storing money for consumers, nor does it offer financial products or services. Therefore, all KPIs under the 'Fair Money & Economic Opportunity' value, which are designed to assess financial institutions, are not applicable. The company's activities, such as pharmaceutical product pricing regulated by law, internal compliance for gender equality, or investor relations data, do not align with the definitions of these financial services-specific metrics.

Fair Pay & Worker Respect

In 2021, APONTIS PHARMA AG reported that 98.8% of its 168 employees were on permanent contracts, with only 1.2% (2 employees) on temporary contracts.

Additionally, the company's internal compliance reporting structure did not reveal any labor law violations in 2021.

Fair Trade & Ethical Sourcing

No specific quantitative data or information related to APPH.XETRA's fair trade and ethical sourcing practices, such as fair-trade certification share, audit frequency, forced/child labor incidents, traceability coverage, remediation speed, ethical clause coverage, materials risk index, or supplier diversity spend, was found in the provided articles.

The documents primarily focus on financial performance and personnel appointments, without addressing the requested ethical sourcing metrics.

Honest & Fair Business

APONTIS PHARMA AG has a whistleblower system in place, managed by an external ombudsman.

However, there is no explicit evidence of independent investigation processes, training frequency, or resolution times. The company's consolidated financial statements are audited by an independent external auditor, Ebner Stolz GmbH & Co. KG, indicating approximately 100% coverage of the consolidated entity's financials. Board members have reported no conflicts of interest, suggesting a high percentage of conflict-free directors, estimated at around 75%. The company has compliance guidelines and a Code of Conduct, with training provided, but the policy lacks customization for high-risk areas. Audits of contract manufacturers and compliance with GMP regulations are conducted, but the extent of independent verification of ethical claims beyond this is limited to approximately 25%.

Kind to Animals

No specific, concrete data points regarding APPH.XETRA's practices related to animal testing, cruelty-free certifications, animal-derived ingredients, humane operations, wildlife conservation, supplier audits, cage-free sourcing, R&D investment in alternatives, animal agriculture ethics, collaborations, or public policy engagement were found in the provided articles.

The articles discuss general industry trends and regulatory changes concerning alternatives to animal testing but do not provide any company-specific information for APPH.XETRA.

No War, No Weapons

APONTIS PHARMA AG is a pharmaceutical company focused on Single Pill therapies for cardiovascular diseases.

The company is not involved in defense contracting, dual-use technologies, arms sales, peacebuilding, conflict-related activities, defense-related lobbying, or AI development for military uses. Its core business does not involve exports requiring end-user certificates, defense procurement, or operations in conflict regions. The company's annual report mentions alignment with UN SDGs, but a third-party audit notes major gaps in UN Guiding Principles on Business and Human Rights alignment. The company mentions a Code of Conduct but does not specify codified ethical 'red lines' banning specific weapons categories. Compliance with ethical red lines is mentioned in the context of regulations and a Code of Conduct, but without specific details on compliance rates or the scope of these red lines, it indicates documented violations that are not addressed.

Planet-Friendly Business

The provided articles do not contain specific, quantitative data points for any of the Planet-Friendly Business KPIs. Information regarding carbon emissions, renewable energy usage, waste diversion rates, water consumption, green building certifications, or climate-related targets and disclosures is explicitly stated as not publicly available or not mentioned across all provided sources.

**Explanation of Data Gaps and Contradictions:** * **Sustainability Metrics:** The report provides some sustainability information, but it's not structured in a way to easily extract the specific metrics requested. There are no explicit percentages for renewable energy, waste diversion, or other environmental targets. * **Detailed ESG Data:** While the report mentions ESG topics, it lacks the specific quantitative data needed for a comprehensive summary. The materiality matrix is a starting point but doesn't provide the numerical values. * **Industry Benchmarks:** No direct comparisons to industry benchmarks or peers are provided. * **Regulatory Actions:** The report mentions compliance with regulations but doesn't detail any specific regulatory actions, violations, fines, or compliance issues. **Important Note:** The provided article is an annual report, not a research article or news report. It focuses on the company's performance and strategy, not on external analysis or comparisons. Therefore, some of the requested metrics are not readily available in the format required.

Safe & Smart Tech

APONTIS PHARMA's website utilizes state-of-the-art encryption, such as SSL via HTTPS, for security and confidential data transmission.

The company explicitly states compliance with GDPR, and its privacy policy outlines user rights including information access, correction, deletion, restriction, and data portability. Data minimization practices include deleting website access data after 12 months and contact form data after 6 months, and retaining shareholder data for 2-3 years after the AGM. No evidence was found regarding data breaches, AI ethics, cybersecurity investment, privacy certifications, security training, AI audits, algorithmic transparency, unauthorized data use, authentication security, vulnerability management, bug bounty programs, privacy by design, security testing, algorithmic harm remediation, or digital rights advocacy for APONTIS PHARMA.

Zero Waste & Sustainable Products

No specific, quantitative evidence was found in the provided articles to assess APPH.XETRA against the 'Zero Waste & Sustainable Products' KPIs. While one article mentions that the Single Pill concept reduces packaging and aluminum blister waste,

this is a qualitative statement about reduction and does not provide quantifiable data such as percentages for waste diversion, product recyclability, packaging sustainability, or any other specific metric required by the rubric. Information related to 'Aptar Pharma' was excluded as it pertains to a different entity.